Neuroblastoma represents 8-10 % of all malignant tumors in childhood and is responsible for 15 % of cancer deaths in the pediatric population. Aggressive neuroblastomas are often resistant to chemotherapy. Canonically, neuroblastomas can be classified according to the MYCN (N-myc proto-oncogene protein) gene amplification, a common marker of tumor aggressiveness and poor prognosis. It has been found that certain compounds with chelating properties may show anticancer activity, but there is little evidence for the effect of chelators on neuroblastoma. The effect of new chelators characterized by the same functional group, designated as HLZ (1-hydrazino phthalazine), on proliferation (WST-1 and methylene blue assay), cell cycle (flow cytometry), apoptosis (proliferation assay after use of specific pharmacological inhibitors and western blot analysis) and ROS production (fluorometric assay based on dichlorofluorescein diacetate metabolism) was studied in three neuroblastoma cell lines with different levels of MYCN amplification. The molecules were effective only on MYCN-non-amplified cells in which they arrested the cell cycle in the G0/G1 phase. We investigated the mechanism of action and identified the activation of cell signaling that involves protein kinase C.

Department of Biochemistry and Microbiology University of Chemistry and Technology Prague 6 Czech Republic; Institute of Medical Biology Genetics and Clinical Genetics Faculty of Medicine Comenius University in Bratislava Bratislava Slovak Republic

Zobrazit více v PubMed

Davis AE. Thesis. University of South Carolina; Columbia, USA: 2012. Neuroblastoma: A Theoretical Dose Dependent Drug Study With Therapeutic Implications.

Mohan N. Ph. D. Thesis. University of South Carolina; Columbia, USA: 2012. Combination Therapy for the Treatment of Human Malignant Neuroblastoma.

Balaraman P. Ph. D. Thesis. University College; London, London, Great Britain: 2005. An Investigation of the Mechanism of Cisplatinum-Induced Apoptosis in SH-SY5Y Neuroblastoma Cells.

Monclair T, Brodeur GM, Ambros PF, Brisse HJ, et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. J Clin Oncol. 2009;27:298–303. doi: 10.1200/JCO.2008.16.6876. PubMed DOI PMC

Kojima M, Hiyama E, Fukuba I, Yamaoka E, Ueda Y, Onitake Y, Kurihara S, Sueda T. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma. Pediatr Surg Int. 2013;29:1139–1145. doi: 10.1007/s00383-013-3374-9. PubMed DOI

Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003;4:472–480. doi: 10.1016/S1470-2045(03)01166-5. PubMed DOI

Seeger RC, Brodeur GM. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med. 1985;313:1111–1116. doi: 10.1056/NEJM198510313131802. PubMed DOI

Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res. 1997;3:1699–1706. PubMed

Chayka O, D’Acunto CW, Middleton O, Arab M, Sala A. Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor Cells. J Biol Chem. 2015;290:2198–2212. doi: 10.1074/jbc.M114.624056. PubMed DOI PMC

Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006;40:14901–14906. doi: 10.1073/pnas.0604979103. PubMed DOI PMC

Zhou T, Ma Y, Kong X, Hider RC. Design of iron chelators with therapeutic application. R Soc Chem. 2012;41:6371–6389. doi: 10.1039/c2dt12159j. PubMed DOI

Shen L, Zhao HY, Du J, Wang F. Anti-tumor activities of four chelating agents against human neuroblastoma cells. In vivo. 2005;19:233–236. PubMed

Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997;1331:1–40. doi: 10.1016/S0304-4157(96)00014-7. PubMed DOI

Keer HN, Kozlowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol. 1990;143:381–385. doi: 10.1016/S0022-5347(17)39970-6. PubMed DOI

Bierings MB, Baert MR, van Eijk HG, van Dijk JP. Transferrin receptor expression and the regulation of placental iron uptake. Mol Cell Biochem. 1991;100:31–38. doi: 10.1007/BF00230807. PubMed DOI

Buss JL, Greene BT, Turner J, Torti FM, Torti SV. Iron chelators in cancer chemotherapy. Curr Top Med Chem. 2004;4:1623–1635. doi: 10.2174/1568026043387269. PubMed DOI

Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res. 1991;51:1426–1433. PubMed

Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009;1790:702–717. doi: 10.1016/j.bbagen.2008.04.003. PubMed DOI

Fan L, Iyer J, Zhu S, Frick KK, Wada RK, Eskenazi AE, et al. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res. 2001;61:1073–1079. PubMed

Blatt J, Stitely S. Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res. 1987;47:1749–1750. PubMed

Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol. 2002;42:267–281. doi: 10.1016/S1040-8428(01)00218-9. PubMed DOI

D’Acunto CW, Kaplánek R, Gbelcová H, Kejík Z, Bříza T, Vasina L, Havlík M, Ruml T, Král V. Metallomics for Alzheimer’s disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties. Eur J Med Chem. 2018;150:140–155. doi: 10.1016/j.ejmech.2018.02.084. PubMed DOI

Kaplánek R, Havlík M, Dolenský B, Rak J, et al. Synthesis and biological activity evaluation of hydrazone derivatives based on a Tröger’s base skeleton. Bioorg Med Chem. 2015;23:1651–1659. doi: 10.1016/j.bmc.2015.01.029. PubMed DOI

Corvetta D, Chayka O, Gherardi S, D’Acunto CW, Džubák P, Konečný P, Hajdúch M, et al. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. J Biol Chem. 2013;288:8332–8341. doi: 10.1074/jbc.M113.454280. PubMed DOI PMC

Nghia TV, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochem Biophys Acta. 2002;1603:31–46. doi: 10.1016/S0304-419X(02)00068-9. PubMed DOI

Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol. 1992;15:319–322. doi: 10.1097/00000421-199208000-00009. PubMed DOI

Richardson DR. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem. 2005;12:2711–2729. doi: 10.2174/092986705774462996. PubMed DOI

Salis O, Bedir A, Kilinc V, Alacam H, Gulten S, Okuyucu A. The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells. Cancer Biomark. 2014;14:419. doi: 10.3233/CBM-140422. PubMed DOI

Bajbouj K, Shafarin J, Hamad M. High-dose deferoxamine treatment disrupts intracellular iron homeostasis, reduces growth, and induces apoptosis in metastatic and nonmetastatic breast cancer cell lines. Technol Cancer Res Treat. 2018;17:1533033818764470. doi: 10.1177/1533033818764470. PubMed DOI PMC

Corcé V, Gouin S, Renaud S, Gaboriau F, Deniaud D. Recent advances in cancer treatment by iron chelators. Bioorganic Med Chem Lett. 2016;26:251–256. doi: 10.1016/j.bmcl.2015.11.094. PubMed DOI

Kim JL, Lee DH, Na YJ, Kim BR, Jeong YA, Lee SI, Kang S, et al. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells. Tumour Biol. 2016;37:9709–9719. doi: 10.1007/s13277-016-4878-4. PubMed DOI

Abdelaal G, Veuger S. Reversing oncogenic transformation with iron chelation. Oncotarget. 2021;12:106–124. doi: 10.18632/oncotarget.27866. PubMed DOI PMC

Yu Y, Richardson DR. Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem. 2011;286:15413–15427. doi: 10.1074/jbc.M111.225946. PubMed DOI PMC

Choi EY, Lee S, Oh H-M, Kim Y-D, Choi E-J, Kim S-H, Kim S-W, et al. Involvement of protein kinase Cdelta in iron chelator-induced IL-8 production in human intestinal epithelial cells. Life Sci. 2007;80:436–445. doi: 10.1016/j.lfs.2006.09.044. PubMed DOI

Perez LM, Milkiewicz P, Ahmed-Choudhury J, Elias E, Ochoa JE, Sánchez Pozzi EJ, Coleman R, Roma MG. Oxidative stress induces actin-cytoskeletal and tight-junctional alterations in hepatocytes by a Ca2+-dependent, PKC-mediated mechanism: protective effect of PKA. Free Radic Biol Med. 2006;40:2005–2017. doi: 10.1016/j.freeradbiomed.2006.01.034. PubMed DOI

Flora SJS, Mittal M, Mehta A. Heavy metal induced oxidative stress and its possible reversal by chelation therapy. Indian J Med Res. 2008;128:501–523. PubMed

Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang G, Brockhaus M, Müller-Spahn F. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased β-amyloid secretion. J Pineal Res. 2001;31:320–325. doi: 10.1034/j.1600-079X.2001.310406.x. PubMed DOI

Ho VT, Bunn HF. Effects of transition metals on the expression of the erythropoietin gene: further evidence that the oxygen sensor is a heme protein. Biochem Biophys Res Commun. 1996;223:175–180. doi: 10.1006/bbrc.1996.0865. PubMed DOI

Gottwald EM, Schuh CD, Drücker P, Haenni D, Pearson A, Ghazi S, Bugarski M, et al. The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability. Sci Rep. 2020;10:1577. doi: 10.1038/s41598-020-58386-9. PubMed DOI PMC

Macsek P, Skoda J, Krchniakova M, Neradil J, Veselska R. Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma. Int J Mol Sci. 2021;23:376. doi: 10.3390/ijms23010376. PubMed DOI PMC